FibroGen to Report Third Quarter 2025 Financial Results

Core Insights - FibroGen, Inc. will announce its third quarter 2025 financial results on November 10, 2025, after market close, followed by a conference call at 5:00 PM Eastern Time to discuss corporate and financial performance [1] Group 1: Financial Results Announcement - The financial results for the third quarter of 2025 will be disclosed on November 10, 2025, after market close [1] - A conference call will be held on the same day at 5:00 PM Eastern Time to provide further details on the company's performance [1] Group 2: Conference Call and Webcast - The FibroGen management team will host a conference call and webcast presentation to discuss financial results and provide a business update [2] - A live Q&A session will follow the presentation, and interested parties can access the live audio webcast [2] Group 3: Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia [3] - Roxadustat is approved in multiple regions, including China, Europe, and Japan, for treating anemia in chronic kidney disease patients [3] - The company is evaluating a Phase 3 trial for roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. [3] - FG-3246, a first-in-class antibody-drug conjugate targeting CD46, is in Phase 2 development for metastatic castration-resistant prostate cancer [3]